Skip to content
Home » Archives for Eleanor Howe » Page 2

Eleanor Howe

When to Hire a Consultant vs. Build an In-House Bioinformatics Team

In today’s data-driven life sciences landscape, bioinformatics isn’t just a support function – it’s central to planning, decision-making, and competitive differentiation. Whether you’re launching your first program or managing a global portfolio, one question consistently arises: should you build an internal team or bring in external consultants? There’s no universal answer, but the right choice… Read More »When to Hire a Consultant vs. Build an In-House Bioinformatics Team

You Don’t Need AI for That

Call it snark or pragmatism, but a recent BioBuzz panel, “Leveraging AI Across the BioPharma Value Chain,” brought something rare to the AI conversation: honesty. The panelists didn’t worship at the altar of algorithms. Instead, they asked smart questions. When does AI really add value? When is it just a high-tech answer in search of… Read More »You Don’t Need AI for That

What to Expect From Your First Bioinformatics Consulting Engagement 

If you’ve never partnered with a bioinformatics consulting firm, you might imagine the process involves tossing your precious data into a mysterious black box, crossing your fingers, and hoping useful insights magically emerge. At Diamond Age Data Science, we know that real magic happens when biology meets data science, clear communication meets collaboration, and complex… Read More »What to Expect From Your First Bioinformatics Consulting Engagement 

Ask the Right Questions Before Choosing a Bioinformatics Partner

Thinking about expanding your bioinformatics capabilities by hiring expert consultants? It might feel like the answer is as simple as finding someone to analyze your data, but the truth is, this decision can make or break your research. A great bioinformatics partner isn’t just a number-cruncher—they’re a partner who gets your science, aligns with your… Read More »Ask the Right Questions Before Choosing a Bioinformatics Partner

Rapid Genomic Analysis Clears FDA Hurdle

Challenge A pharmaceutical company faced a critical situation when they reported a seriousadverse event (SAE) for a patient enrolled in their clinical trial. Swift action was neededto respond to the FDA’s questions, safeguard patients, and prevent disruptions to thetrial. However, addressing FDA’s questions presented a formidable challenge because itrequired extensive, non-standard genomic analyses to establish… Read More »Rapid Genomic Analysis Clears FDA Hurdle

Evaluating Emerging Technologies With Minimal Investment

  Challenge A client of Diamond Age (DA) wanted to evaluate the utility of emerging spatial transcriptomics technologies to advance their efforts in targeting treatments to specific body tissues. The client’s needs were two-fold: first, to address specific questions about their treatment in vivo, and second, to assess the technology for future use. However, the… Read More »Evaluating Emerging Technologies With Minimal Investment

Streamlining Omics Data Analysis for Faster Decision-Making

Challenge: Inefficiencies in omics dataset formats caused a therapeutics company costly delays A therapeutics company struggled to use public omics datasets to guide critical portfolio decisions. These decisions included identifying patient population sizes for different targets, evaluating opportunities for indication expansion to determine where their therapy might be most effective, and selecting the most appropriate… Read More »Streamlining Omics Data Analysis for Faster Decision-Making

Skip to content